A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine

Starling, Amaal J.; Vargas, Bert B.

doi:10.1007/s11916-015-0521-0

Cited by 17 publications

(12 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pharmacotherapy of migraine headache prophylaxis begins with the goals of therapy in mind . Drug therapy considerations include the evidence available supporting its efficacy, adverse event profile and the presence of comorbid conditions . Consideration should be given to medications with Level A ratings by the American Academy of Neurology (AAN) .…”

Section: What Is Known and Objectivementioning

confidence: 99%

“…10,11 Drug therapy considerations include the evidence available supporting its efficacy, adverse event profile and the presence of comorbid conditions. [12][13][14] Consideration should be given to medications with Level A ratings by the American Academy of Neurology (AAN). 6,15 These drugs include sodium valproate, topiramate, certain beta-blockers (metoprolol and propranolol), and frovatriptan.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prophylaxis of migraine headaches with riboflavin: A systematic review

Thompson

Saluja

2017

J Clin Pharm Ther

View full text Add to dashboard Cite

SummaryWhat is known and objective: Migraine headache is a relatively common, debilitating condition that costs our healthcare system over 78 billion dollars per year. Riboflavin has been advocated as a safe, effective prophylactic therapy for the prevention of migraines. The purpose of this study was to provide a systematic review of the current role of riboflavin in the prophylaxis of migraine headache. Methods What is new and conclusion:Riboflavin is well tolerated, inexpensive and has demonstrated efficacy in the reduction of adult patient's migraine headache frequency.Additional data are needed, however, to resolve questions involving pharmacokinetic issues and pharmacogenomic implications of therapy. K E Y W O R D Smigraine, pharmacogenomics, pharmacokinetics, riboflavin | WHAT IS KNOWN AND OBJECTIVEMigraine headache is a common, often disabling neurologic condition characterized by painful headaches associated with nausea, vomiting, and hypersensitivity to visual, auditory, and olfactory stimuli. The worldwide prevalence of migraine headache is about 10%; however, it is slightly higher in the United States at 12%.1,2 Women experience migraine headache at a greater rate (15%-17%) as compared to men. 1,3Epidemiologic data suggest that while 38% of patients with migraine headache need prophylactic therapy, only 3%-13% currently take prophylactic treatment. 4 Prophylactic therapy should be considered in situations where the patient feels that the recurring migraine headaches interfere with their daily routines and responsibilities despite acute treatment. 1-4The goals of treatment for patients requiring prophylactic therapy are to decrease the frequency, duration and severity of attacks,

show abstract

Section: What Is Known and Objectivementioning

confidence: 99%

mentioning

confidence: 99%

Prophylaxis of migraine headaches with riboflavin: A systematic review

Thompson

Saluja

2017

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…The prevalence of migraine in the U.S. is high, affecting approximately 14% of adults annually, of which approximately 15% have chronic migraine [139,140]. CM patients are much more likely to experience severe impact from migraine (interference with work, school or social activities, severe pain, fatigue, frustration, difficulty concentrating) relative to EM patients (72.9% vs. 42.3%).…”

Section: Migrainementioning

confidence: 99%

Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders

Tait¹,

Ferguson²,

Herndon³

2017

Pain Manage Med

View full text Add to dashboard Cite

Chronic orofacial pain is a symptom associated with a wide range of neuropathic, neurovascular, idiopathic, and myofascial conditions that affect a significant proportion of the population. While the collective impact of the subset of the orofacial pain disorders involving neurogenic and idiopathic mechanisms is substantial, some of these are relatively uncommon. Hence, patients with these disorders can be vulnerable to misdiagnosis, sometimes for years, increasing the symptom burden and delaying effective treatment. This manuscript first reviews the decision tree to be followed in diagnosing any neuropathic pain condition, as well as the levels of evidence needed to make a diagnosis with each of several levels of confidence: definite, probable, or possible. It then examines the clinical literature related to the idiopathic and neurogenic conditions that can occasion chronic orofacial pain, including burning mouth syndrome, trigeminal neuralgia, glossopharyngeal neuralgia, post-herpetic neuralgia, and atypical odontalgia. Temporomandibular disorders also are examined as are other headache conditions, even though they are not neurologic conditions, because they are common and can mimic symptoms of the latter disorders. For each of these conditions, the paper reviews literature regarding incidence and prevalence, physiologic and other contributing factors, diagnostic signs and symptoms, and empirical evidence regarding treatments. Finally, in order to improve the quality and accuracy of clinical diagnosis, as well as the efficiency with which effective treatment is initiated and delivered, criteria are offered that can be instrumental in making a differential diagnosis.

show abstract

“…Oral medications that are commonly used include antiepileptics, such as topiramate; antihypertensives, such as beta blockers; and antidepressants, such as tricyclic antidepressants. 10 , 11 Flunarizine is also considered a drug of first choice for the prophylaxis of migraine in Europe. 8 Among these medications, topiramate has been shown to be effective in large, randomized placebo-controlled trials of patients with chronic migraine.…”

Section: Introductionmentioning

confidence: 99%

OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience

Chiang

Starling

2017

Ther Adv Neurol Disord

Self Cite

View full text Add to dashboard Cite

Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4–2.2% of the population worldwide. Patients with chronic migraine have 15 or more headache days per month, with at least 8 days per month that meet the criteria for migraine. Injection of onabotulinumtoxinA, using a standardized injection protocol, was approved by the US Food and Drug Administration in 2010 for the treatment of chronic migraine. The approval was made based on results from two large, randomized, double-blind placebo-controlled trials: the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials. Since then, numerous studies have been performed investigating the short-term and long-term benefits, risks and complications of the use of onabotulinumtoxinA injections for the treatment of chronic migraine. The purpose of this narrative review is to describe the currently available clinical evidence for the use of onabotulinumtoxinA injections for treating patients with chronic migraine.

show abstract

A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine

Cited by 17 publications

References 40 publications

Prophylaxis of migraine headaches with riboflavin: A systematic review

Prophylaxis of migraine headaches with riboflavin: A systematic review

Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders

OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience

Contact Info

Product

Resources

About